	US 11,666,560 B2
	Anti-fibrotic agent
Mikell Paige, Fairfax, VA (US); Gregory Petruncio, Fairfax, VA (US); and Yun Michael Shim, Charlottesville, VA (US)
Assigned to George Mason University, Fairfax, VA (US)
Filed by George Mason University, Fairfax, VA (US)
Filed on Sep. 24, 2020, as Appl. No. 17/31,183.
Prior Publication US 2022/0087986 A1, Mar. 24, 2022
Int. Cl. C07D 225/00 (2006.01); A61K 31/436 (2006.01); A61K 31/439 (2006.01); A61P 11/00 (2006.01)

CPC A61K 31/439 (2013.01) [A61P 11/00 (2018.01)]

12 Claims

1. A method to treat a pulmonary fibrosis comprising administering a compound in a mammalian subject and treating the mammalian subject, wherein the compound is configured to reduce the pulmonary fibrosis in the mammalian subject, wherein the compound comprises a peptidyl-prolyl cis-trans isomerase binding region and a blocked calcineurin binding region, and optionally a solvent accessible region,

wherein the compound is represented by Formula II